Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 15/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.34 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.34 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4143591 | 0.84 | MAOA (0.43) | ALOX5CISD1 | |
| SCHEMBL4143594 | 0.84 | MAOA (0.43) | ALOX5CISD1 | |
| SCHEMBL4140156 | 0.78 | HDAC1 (0.32) | ALOX5CISD1MAPT | |
| SCHEMBL4140153 | 0.78 | HDAC1 (0.32) | ALOX5CISD1MAPT | |
| SCHEMBL4128820 | 0.77 | KMT2A (0.47) | ALOX5CISD1POLBMAPT | |
| SCHEMBL4128816 | 0.77 | KMT2A (0.47) | ALOX5CISD1POLBMAPT | |
| SCHEMBL4133274 | 0.77 | MEN1 (0.41) | ALOX5CISD1POLBMAPT | |
| SCHEMBL4133272 | 0.77 | MEN1 (0.41) | ALOX5CISD1POLBMAPT | |
| SCHEMBL4128197 | 0.76 | ALOX5 (0.41) | ALOX5POLBMAPT | |
| SCHEMBL4128194 | 0.76 | ALOX5 (0.41) | ALOX5POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | ALOX5 3505/4885SLC1A3 3975/4885SLC1A2 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.